AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3986113 — intervention group
Group type: COMPARATOR
Intervention: Bolus lignocaine
Number of subjects: 52
Study 30024484 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (provided FMS grading criteria)
Number of subjects: 32
Study 30024484 — intervention group
Group type: COMPARATOR
Intervention: Control group (not provided FMS grading criteria)
Number of subjects: 32
Study 31675102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8)
Number of subjects: 1130
Study 31675102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (675 mg at baseline, 225 mg at weeks 4 and 8)
Number of subjects: 1130
Study 31675102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1130
Study 31675102 — intervention group
Group type: EXPERIMENTAL
Intervention: All fremanezumab groups (quarterly and monthly combined)
Number of subjects: 1130
Study 30404123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided betamethazone injections
Number of subjects: 44
Study 30404123 — intervention group
Group type: COMPARATOR
Intervention: Blind injections (palpation-guided)
Number of subjects: 44
Study 27385305 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological therapy (adalimumab, etanercept, infliximab, ustekinumab)
Number of subjects: 28
Study 27385305 — intervention group
Group type: COMPARATOR
Intervention: Control group (no systemic therapy)
Number of subjects: 28
Study 27385305 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological therapy
Number of subjects: 28
Study 27385305 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 25207986 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + CBT (16 sessions individual CBT)
Number of subjects: 60
Study 25207986 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 60
Study 22911048 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computerized patient education, skin self-examination tutorials, and telecommunication reminders for 12 weeks.
Number of subjects: 132
Study 22911048 — intervention group
Group type: COMPARATOR
Intervention: Brochure on melanoma detection (control group).
Number of subjects: 132
Study 20441726 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 60
Study 20441726 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 60
Study 18042053 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 22
Study 18042053 — intervention group
Group type: EXPERIMENTAL
Intervention: atorvastatin 20 mg
Number of subjects: 22
Study 16089140 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified shenqi fanghou recipe (SFR) as adjuvant to radiotherapy
Number of subjects: 140
Study 16089140 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (Control)
Number of subjects: 140
Study 12095058 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10mg/day
Number of subjects: 58
Study 12095058 — intervention group
Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 58
Study 10434812 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg kg‐1 followed by 10‐6 mg kg‐1 h‐1)
Number of subjects: 30
Study 10434812 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-nitrous oxide
Number of subjects: 30
Study 10434812 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.3 mg kg‐1 followed by 0.15 mg kg‐1 h‐1)
Number of subjects: 30
Study 7779222 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2338118 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate with milk
Number of subjects: 6
Study 2338118 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate with food
Number of subjects: 6
Study 2338118 — intervention group
Group type: COMPARATOR
Intervention: Estramustine phosphate with low calcium water
Number of subjects: 6
Study 205633 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose ethanol treatment
Number of subjects: 18
Study 205633 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide treatment
Number of subjects: 18
Study 30767253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 49
Study 30767253 — intervention group
Group type: COMPARATOR
Intervention: Vildagliptin
Number of subjects: 49
Study 27648814 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 196
Study 27648814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 25844613 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week maintenance therapy with a cosmeceutical formulation containing hydroxyphenoxy propionic acid, ellagic acid, yeast extract, and salicylic acid
Number of subjects: 33
Study 23844003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia-care mapping (DCM) intervention conducted by trained nursing staff over 4 months.
Number of subjects: 434
Study 23844003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia-care mapping (DCM) intervention
Number of subjects: 434
Study 23844003 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 434
Study 21296603 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0
Study 21296603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18585822 — intervention group
Group type: EXPERIMENTAL
Intervention: Death certificate data
Number of subjects: 237
Study 18585822 — intervention group
Group type: EXPERIMENTAL
Intervention: Death certificates
Number of subjects: 237
Study 16412857 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin (ATV)
Number of subjects: 15
Study 16412857 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 15
Study 15222854 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional words
Number of subjects: 0
Study 15222854 — intervention group
Group type: COMPARATOR
Intervention: Neutral words
Number of subjects: 0
Study 11910619 — intervention group
Group type: COMPARATOR
Intervention: Esterified estrogens 0.3 mg daily (long-term study)
Number of subjects: 204
Study 11910619 — intervention group
Group type: EXPERIMENTAL
Intervention: Esterified estrogens 0.3 mg daily (short-term study)
Number of subjects: 204
Study 9057990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive phototherapy with blue light
Number of subjects: 10
Study 9057990 — intervention group
Group type: COMPARATOR
Intervention: Intensive phototherapy with green light
Number of subjects: 10
Study 8378661 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg q.p.m. initially, increased to 40 mg q.p.m. for 64% of patients after 18 weeks)
Number of subjects: 136
Study 8378661 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil (900 mg q.p.m.)
Number of subjects: 136
Study 3796783 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low protein intake (0.4 g/kg/day) supplemented with keto analogues of essential amino acids
Number of subjects: 19
Study 3796783 — intervention group
Group type: COMPARATOR
Intervention: Standard low protein diet (0.6 g/kg/day)
Number of subjects: 19
Study 31012563 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% BPO cleanser
Number of subjects: 133
Study 31012563 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% BPO cleanser
Number of subjects: 133
Study 31012563 — intervention group
Group type: COMPARATOR
Intervention: Reference product (10% BPO)
Number of subjects: 133
Study 29125992 — intervention group
Group type: EXPERIMENTAL
Intervention: FVOO (500 ppm)
Number of subjects: 33
Study 29125992 — intervention group
Group type: EXPERIMENTAL
Intervention: FVOOT (500 ppm)
Number of subjects: 33
Study 29125992 — intervention group
Group type: COMPARATOR
Intervention: VOO (80 ppm)
Number of subjects: 33
Study 26935962 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction group (multiband treatment plus isolated extraction of mandibular teeth)
Number of subjects: 46
Study 26935962 — intervention group
Group type: COMPARATOR
Intervention: Non-extraction group (multiband treatment without extraction of teeth)
Number of subjects: 46
Study 26935962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 25365567 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive game with a confederate
Number of subjects: 0
Study 25365567 — intervention group
Group type: COMPARATOR
Intervention: Cooperative game with a confederate
Number of subjects: 0
Study 25365567 — intervention group
Group type: COMPARATOR
Intervention: Observation without playing
Number of subjects: 0
Study 25365567 — intervention group
Group type: EXPERIMENTAL
Intervention: Players who lost the competition
Number of subjects: 0
Study 25365567 — intervention group
Group type: COMPARATOR
Intervention: Players who won the competition
Number of subjects: 0
Study 22644342 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 2 g administered simultaneously with triazolam 0.25 mg
Number of subjects: 12
Study 22644342 — intervention group
Group type: COMPARATOR
Intervention: Triazolam 0.25 mg alone
Number of subjects: 12
Study 22644342 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 2 g administered 30 or 60 min before triazolam 0.25 mg
Number of subjects: 12
Study 20053413 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour drainage (Group I)
Number of subjects: 65
Study 20053413 — intervention group
Group type: EXPERIMENTAL
Intervention: 96-hour drainage (Group II)
Number of subjects: 65
Study 18853553 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of a dynamic object
Number of subjects: 0
Study 15740547 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (1.5 or 3 mg/d)
Number of subjects: 779
Study 15740547 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (standard concentration range)
Number of subjects: 779
Study 12194379 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10407881 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy during recovery period
Number of subjects: 20
Study 10407881 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lavender aromatherapy) during recovery period
Number of subjects: 20
Study 7750306 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP), 400 micrograms, two times daily
Number of subjects: 56
Study 2248822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with adrenaline 5 micrograms ml‐1
Number of subjects: 16
Study 2248822 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine without adrenaline (plain bupivacaine)
Number of subjects: 16
Study 2248822 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without adrenaline)
Number of subjects: 16
Study 7028536 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 150 mg
Number of subjects: 6
Study 7028536 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg
Number of subjects: 6
Study 7028536 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox 400 mg
Number of subjects: 6
Study 7028536 — intervention group
Group type: COMPARATOR
Intervention: Food effect
Number of subjects: 6
Study 30893217 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral knees and randomly selected knees from the bilateral group (n = 217)
Number of subjects: 217
Study 30893217 — intervention group
Group type: EXPERIMENTAL
Intervention: Males (n not specified)
Number of subjects: 217
Study 30893217 — intervention group
Group type: EXPERIMENTAL
Intervention: Females (n not specified)
Number of subjects: 217
Study 30893217 — intervention group
Group type: EXPERIMENTAL
Intervention: Right knees (n not specified)
Number of subjects: 217
Study 30893217 — intervention group
Group type: EXPERIMENTAL
Intervention: Left knees (n not specified)
Number of subjects: 217
Study 28654771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Group Therapy (CBGT)
Number of subjects: 108
Study 28654771 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR)
Number of subjects: 108
Study 26384729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nail fixation
Number of subjects: 320
Study 26384729 — intervention group
Group type: COMPARATOR
Intervention: Plate and locking screw fixation
Number of subjects: 320
Study 23428941 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat/energy condition
Number of subjects: 47
Study 23428941 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition
Number of subjects: 47
Study 23428941 — intervention group
Group type: COMPARATOR
Intervention: High fat/energy condition
Number of subjects: 47
Study 21352660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized bronchodilator + oxygen + forward‐leaning posture
Number of subjects: 59
Study 21352660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized bronchodilator + heliox + forward‐leaning posture
Number of subjects: 59
Study 21352660 — intervention group
Group type: COMPARATOR
Intervention: Nebulized bronchodilator + heliox
Number of subjects: 59
Study 19702064 — intervention group
Group type: EXPERIMENTAL
Intervention: New-design extended tip modified Ayre's spatula
Number of subjects: 200
Study 19702064 — intervention group
Group type: COMPARATOR
Intervention: Conventional modified Ayre's spatula
Number of subjects: 200
Study 17355549 — intervention group
Group type: EXPERIMENTAL
Intervention: Active preparation (cannabis-based medicine containing THC and CBD)
Number of subjects: 189
Study 17355549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 15566533 — intervention group
Group type: EXPERIMENTAL
Intervention: Incognito standardised patients (SPs) as known patients
Number of subjects: 49
Study 15566533 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation of patient records for SP visits
Number of subjects: 49
Study 11572286 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral B 40
Number of subjects: 104
Study 11572286 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Spin Brush
Number of subjects: 104
Study 11572286 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate ActiBrush
Number of subjects: 104
Study 11572286 — intervention group
Group type: COMPARATOR
Intervention: Control (Manual Toothbrush)
Number of subjects: 104
Study 9541513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin 50 IU
Number of subjects: 30
Study 9541513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin 100 IU
Number of subjects: 30
Study 9541513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin 200 IU
Number of subjects: 30
Study 9541513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (all dosages)
Number of subjects: 30
Study 7836548 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding with neo/chol
Number of subjects: 14
Study 7836548 — intervention group
Group type: COMPARATOR
Intervention: Feeding in control Gilbert's patients
Number of subjects: 14
Study 7836548 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding in neo/chol‐treated normals
Number of subjects: 14
Study 7836548 — intervention group
Group type: COMPARATOR
Intervention: Feeding in control normals
Number of subjects: 14
Study 7836548 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and neo/chol in patients with Gilbert's syndrome
Number of subjects: 14
Study 7836548 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed and control state in patients with Gilbert's syndrome
Number of subjects: 14
Study 3278927 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG plus Methenolone (3 mg/kg)
Number of subjects: 30
Study 3278927 — intervention group
Group type: COMPARATOR
Intervention: ATG only
Number of subjects: 30
Study 3278927 — intervention group
Group type: EXPERIMENTAL
Intervention: Total population
Number of subjects: 30
Study 29680277 — intervention group
Group type: EXPERIMENTAL
Intervention: Snodgrass repair
Number of subjects: 60
Study 29680277 — intervention group
Group type: COMPARATOR
Intervention: Grafted tubularized incised plate repair (GTIP)
Number of subjects: 60
Study 29680277 — intervention group
Group type: COMPARATOR
Intervention: Flow rate data
Number of subjects: 60
Study 29680277 — intervention group
Group type: COMPARATOR
Intervention: Operative time
Number of subjects: 60
Study 27896236 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO-WHEY
Number of subjects: 66
Study 27896236 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA
Number of subjects: 66
Study 27896236 — intervention group
Group type: COMPARATOR
Intervention: Control (no nutritional supplement)
Number of subjects: 66
Study 24789659 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-axis technique
Number of subjects: 50
Study 24789659 — intervention group
Group type: COMPARATOR
Intervention: Short-axis technique
Number of subjects: 50
Study 22550938 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care measurement of BNP (n = 163)
Number of subjects: 323
Study 22550938 — intervention group
Group type: COMPARATOR
Intervention: Standard assessment without BNP (n = 160)
Number of subjects: 323
Study 20890856 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT
Number of subjects: 187
Study 20890856 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 187
Study 20890856 — intervention group
Group type: EXPERIMENTAL
Intervention: TOT
Number of subjects: 187
Study 18600443 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG measurements (frontalis, masseter, trapezius muscles)
Number of subjects: 60
Study 18600443 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance level (SCL)
Number of subjects: 60
Study 18600443 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin temperature
Number of subjects: 60
Study 18600443 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative scores of all parameters
Number of subjects: 60
Study 15933235 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental consent quality and understanding of the trial
Number of subjects: 347
Study 15933235 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental knowledge of trial details
Number of subjects: 347
Study 15933235 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental decision-making
Number of subjects: 347
Study 12641528 — intervention group
Group type: EXPERIMENTAL
Intervention: One to eight hours of literature search and retrieval training
Number of subjects: 0
Study 12641528 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 0
Study 10331733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 150 mg daily
Number of subjects: 23
Study 10331733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 300 mg daily
Number of subjects: 23
Study 10331733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 600 mg daily
Number of subjects: 23
Study 10331733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 600 mg every 3 days
Number of subjects: 23
Study 7860912 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (10 cm of water)
Number of subjects: 16
Study 7860912 — intervention group
Group type: COMPARATOR
Intervention: Time control (no nasal continuous positive airway pressure)
Number of subjects: 16
Study 1674842 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup of ipecac (SOI) before activated charcoal (AC)
Number of subjects: 70
Study 1674842 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal (AC) alone
Number of subjects: 70
Study 7007060 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.4 +/- 0.15 mg/day)
Number of subjects: 13
Study 31768697 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06439535 plus chemotherapy
Number of subjects: 719
Study 31768697 — intervention group
Group type: COMPARATOR
Intervention: bevacizumab-EU plus chemotherapy
Number of subjects: 719
Study 30988146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200 mg, intravenously/orally, once daily for 6 days
Number of subjects: 598
Study 30988146 — intervention group
Group type: COMPARATOR
Intervention: Linezolid 600 mg, intravenously/orally, twice daily for 10 days
Number of subjects: 598
Study 30988146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate
Number of subjects: 598
Study 30988146 — intervention group
Group type: COMPARATOR
Intervention: Linezolid
Number of subjects: 598
Study 28237411 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorganization of retinal inner layers (DRIL) assessed by spectral‐domain optical coherence tomography (SDOCT)
Number of subjects: 56
Study 26830687 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 120
Study 26830687 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 120
Study 24381025 — intervention group
Group type: EXPERIMENTAL
Intervention: multifactorial, interdisciplinary intervention targeting frailty characteristics with an individualised home exercise programme prescribed in 10 home visits from a physiotherapist
Number of subjects: 241
Study 24381025 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 241
Study 22654199 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus Control Therapy (SCT)
Number of subjects: 179
Study 22654199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy (SRT)
Number of subjects: 179
Study 22654199 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent Intervention (MCI)
Number of subjects: 179
Study 22654199 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control Group
Number of subjects: 179
Study 19818223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodermix cream
Number of subjects: 15
Study 17472577 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 15
Study 17472577 — intervention group
Group type: COMPARATOR
Intervention: Mannitol infusion
Number of subjects: 15
Study 17472577 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemia
Number of subjects: 15
Study 17472577 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion
Number of subjects: 15
Study 15279417 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glaucoma medication (non-selective beta blockers, selective prostaglandin analogues, topical carbonic anhydrase inhibitors)
Number of subjects: 18
Study 15279417 — intervention group
Group type: COMPARATOR
Intervention: Natural tears (control group)
Number of subjects: 18